94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
SYSTEMATIC REVIEW article
Front. Oncol.
Sec. Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1534005
This article is part of the Research TopicNovel Therapeutic Approaches for Biliary Tract Cancer and Hepatocellular Carcinoma, Volume IIView all articles
Clinical significance of HER2 overexpression in biliary tract carcinoma --A Meta Analysis
Provisionally accepted- Mianyang Central Hospital, Mianyang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Previous studies have been inconsistent on the correlation of human epidermal growth factor receptor 2 (HER2) overexpression in biliary tract carcinoma. The objective of this meta analysis was to assess its association with clinicopathological features and prognostic significance of biliary tract carcinoma. The eligible studies were searched in Pubmed, Embase and Web of Science databases. Inclusion criteria were studies of the relationship between HER2 positive expression (ICH :HER2 (+++), FISH:HER2 overexpression, NGS:HER2 overexpression) and prognosis or clinicopathological features of patients with biliary tract carcinoma (BTC). The analysis was conducted according to gender, high differentiation degree, middle differentiation degree, tumor stage, nerve invasion, vascular invasion, lymph node metastasis and pathological diagnosis of patients. ES (Effect Sizes) for 95% confidence intervals (CI) were calculated to examine risk or hazard associations, and heterogeneity and sensitivity analyses were performed. A total of 15 studies were included to evaluate the association of HER2 positive expression with clinicopathological features and survival prognosis. Overall analysis showed that there was no significant relationship between positive/high expression of HER2 and a series of clinical characteristics such as gender, high, middle and low differentiation, tumor stage, vascular invasion, nerve invasion, T stage and pathological type of patients with biliary tract carcinoma. Patients with positive/high expression of HER2 had poor DFS and OS, and poor prognosis. In summary, High HER2 expression is associated with poorer survival outcomes in BTC patients.HER2 overexpression is an adverse prognostic factor in BTC patients. In the future, well-designed clinical studies of large cases of BTC should be carried out to verify the relationship between HER2 overexpression and pathological features and prognosis of BTC patients.
Keywords: HER2 ， Biliary tract carcinoma ， Intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder carcinoma, perihilar cholangiocarcinoma, distal cholangiocarcinoma, Meta analysis HER-2HER2,Human epidermal growth factor 2, BTC,biliary tract carcinoma, CI, confidence intervals, ICC, intrahepatic cholangiocarcinoma, eCCA ,extrahepatic cholangiocarcinoma, GBC, gallbladder carcinoma, pCCA, perihilar Cholangiocarcinoma, dCCA ,distal cholangiocarcinoma
Received: 25 Nov 2024; Accepted: 16 Apr 2025.
Copyright: © 2025 Xu, Li Ang, TANG, Yang and Du. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiaobo Du, Mianyang Central Hospital, Mianyang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.